%0 Journal Article
%T Targeting primary cilia ¨C associated signaling in glioblastoma: guided approach for drug development
%A Elena N. Pugacheva
%A Yuriy Loskutov
%J Archive of "Oncoscience".
%D 2019
%R 10.18632/oncoscience.475
%X Despite unquestionable progress of the recent decades in cancer therapy and anti-cancer drug discovery, the options for glioblastoma (GBM) patients are very limited. Current standard of care includes aggressive surgical resection, radiation therapy, and chemotherapy, however, majority of patients experience recurrence within 32-36 weeks, and median survival is clenching around 10 months. Clearly, there is a need for new strategies to battle GBM. Unfortunately, with GBM we are not on the solid grounds: there is no known common driver mutation to target; the cell lines, commonly used for GBM research, are obsolete, and their origins are in question; even cells GBM arise from, is a topic of harsh debates. Thus, some guidance system would be highly appreciated, a clue towards which signaling cascades are altered and can be targeted
%K cilia
%K glioblastoma
%K signaling
%K proliferation
%K disassembly
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382257/